Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 0.78 |
| ▸ | CDK1 | P06493 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250915 | 0.88 | CHEK1 (1.00) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5250770 | 0.86 | CHEK1 (1.00) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5250020 | 0.84 | CHEK1 (1.00) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5951804 | 0.83 | CHEK1 (0.86) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5952417 | 0.81 | CHEK1 (0.81) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5247504 | 0.80 | CHEK1 (0.77) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5952506 | 0.80 | CHEK1 (0.63) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5249191 | 0.78 | KDR (1.00) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5953062 | 0.78 | CHEK1 (0.74) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5249044 | 0.76 | CHEK1 (0.86) | CHEK1CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | CHEK1 286/4885CDK1 36/4885KDR 2231/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | CHEK1 321/4885CDK1 5/4885KDR 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.